Abstract |
Grid laser therapy has been demonstrated to be of benefit for the treatment of diabetic macular edema. The purpose of the present study was to determine the cost-effectiveness of grid laser therapy for the treatment of diabetic macular edema. The analysis was performed from the perspective of a third-party insurer. Decision analyses and cost-effectiveness analyses were performed by incorporating the data from the Early Treatment Diabetic Retinopathy Study, expected longevity data, and patient-based utilities. Various sensitivity analyses were performed to determine the robustness of the models. Laser treatment conferred an overall improvement in quality-of-life adjusted years of approximately 3 months over the duration of disease for a hypothetical patient. The unadjusted cost per quality-of-life adjusted year (QALY) was US$3,101. Net present value analysis demonstrated that the cost per QALY could increase to $3,655, assuming a 5% discount rate. Overall, grid laser photocoagulation for diabetic macular edema is a very cost-effective treatment based on the results of this cost-utility analysis.
|
Authors | S Sharma, G C Brown, M M Brown, H Hollands, G K Shah |
Journal | Current opinion in ophthalmology
(Curr Opin Ophthalmol)
Vol. 11
Issue 3
Pg. 175-9
(Jun 2000)
ISSN: 1040-8738 [Print] United States |
PMID | 10977223
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Topics |
- Adult
- Cost-Benefit Analysis
- Diabetic Retinopathy
(economics, mortality, surgery)
- Humans
- Laser Coagulation
(economics)
- Macular Edema
(economics, mortality, surgery)
- Models, Econometric
- Prospective Studies
- Quality-Adjusted Life Years
- Survival Rate
- Visual Acuity
|